Mineralys Therapeutics Inc. Common Stock (MLYS)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor in the Graham and Buffett tradition, I look first for a business that earns money and trades below its worth. Mineralys fails the first test: it has no revenue, and in fiscal year 2023, the year ended 2023-12-31, it reported a net loss of $71.9M; in fiscal year 2024, the year ended 2024-12-31, a net loss of $177.8M; and in fiscal year 2025, the year ended 2025-12-31, a net loss of $154.7M. In fiscal Q2 2026, the quarter ended 2026-06-30, the loss was $241.1M, or $2.85 per diluted share. Trailing free cash flow is -$138.8M, and FairStock's FCF yield is -7.5% on the $1.9B market cap at the 2026-10-13 close. FairStock's P/E is -5.00 and P/B is 3.37, so there is no earnings-based bargain here. The balance sheet has low leverage (D/E 0.18), and FairStock's Altman Z-Score of 9.14 suggests solvency is not the immediate issue, but FairStock's Piotroski 0/9 and ROE of -80.88% confirm severe operating weakness. What is the moat? It is a promise: lorundrostat for dysregulated aldosterone. Until approval and commercialization, there is no demonstrated pricing power or durable competitive advantage. The Lynch category is "none" because losses in each of the last four years fit no Lynch mold. Growth is not revenue growth; it is clinical progress. If the drug works in hypertension, chronic kidney disease, or obstructive sleep apnea, the value could be substantial. If trials fail or delays mount, the $1.9B value has little current cash earnings to support it. I would call this speculation on science, not a value investment with a margin of safety.

In plain English: Mineralys is a small biotech developing an oral medicine called lorundrostat for heart, kidney, and sleep-related conditions. It has no reported revenue and has lost money for years. At $21.00 a share on 2026-10-13, the $1.9 billion price looks expensive against today's numbers because there are no profits or positive cash flow to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer